Expertise in
1
conditions

Sandrine Mansard

Clermont-ferrand, FR 
Expertise in
1
conditions
Clermont-ferrand, FR 

Overview

Sandrine Mansard practices practicing medicine in Clermont-ferrand, France.

Ms. Mansard is highly rated in 1 condition, according to our data. Her clinical expertise encompasses Melanoma, Metastatic Brain Tumor, Neuroendocrine Tumor, and Merkel Cell Carcinoma.

She is actively involved in clinical research, co-authoring 40 peer reviewed articles and participating in 3 clinical trials.

Gender

Female

Locations

Clermont-ferrand, France
Other Locations
Avenue de la République
Tours, 37170, France
Bordeaux, France
Amiens, France
Nantes, France
CHU Montpellier
Montpellier, France
CHU Dijon Bourgogne, CHU Le Bocage
Dijon, France
Marseille, France

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Experts who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

3 Clinical Trials

Targeted Radionuclide Therapy for Metastatic Melanoma [131I] ICF01012: Phase I Study
Targeted Radionuclide Therapy for Metastatic Melanoma [131I] ICF01012: Phase I Study
Enrollment Status: Completed
Publish Date: February 13, 2025
Intervention Type: Drug
Study Drug: [131I]ICF01012
Study Phase: Early Phase 1
Nivolumab in Combination With High Dose Radiotherapy at Varied Tumor Sites in Advanced Melanoma and no Prior Antitumoral Treatment
Nivolumab in Combination With High Dose Radiotherapy at Varied Tumor Sites in Advanced Melanoma and no Prior Antitumoral Treatment
Enrollment Status: Completed
Publish Date: November 15, 2023
Intervention Type: Radiation, Biological
Study Drug: Nivolumab
Study Phase: Phase 2
A Randomized Phase 3 Comparison of IMO-2125 With Ipilimumab Versus Ipilimumab Alone in Subjects With Anti-PD-1 Refractory Melanoma (ILLUMINATE-301)
A Randomized Phase 3 Comparison of IMO-2125 With Ipilimumab Versus Ipilimumab Alone in Subjects With Anti-PD-1 Refractory Melanoma (ILLUMINATE-301)
Enrollment Status: Terminated
Publish Date: November 08, 2022
Intervention Type: Drug
Study Drugs: Ipilimumab, IMO-2125
Study Phase: Phase 3
View 2 Less Clinical Trials

40 Total Publications

Impact of melanoma histological regression on first-line immunotherapy response in stage-IV disease.
Impact of melanoma histological regression on first-line immunotherapy response in stage-IV disease.
Journal: Journal of the European Academy of Dermatology and Venereology : JEADV
Published: July 11, 2025

Frequently Asked Questions about Sandrine Mansard

Is Sandrine Mansard a top-rated expert for Melanoma?

MediFind is an objective health platform that identifies experts based on real-world data. Sandrine Mansard is classified as an Distinguished expert for Melanoma, meaning they are among the top experts in the country for this condition. This ranking is based on their volume of patients, published research, and peer connections.

Does Sandrine Mansard participate in research or clinical trials?

Yes. Sandrine Mansard has published 40 articles and abstracts on conditions like Melanoma. You can view a list of Sandrine Mansard's latest peer-reviewed publications and clinical trial participation on their profile to see if they are active in new treatments.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Ms. Mansard's expertise for a condition
ConditionClose
      View All 7 Experienced Conditions
      Want to save this expert for later?
      Sign Up
      Not sure about your diagnosis?
      Check Your Symptoms
       
       
       
       
      Learn about our expert tiers
      Learn More
      Are you the provider on this profile?
      Claim Profile